Immunovaccine to close $10M bought deal

pcNewsWireImmunovaccine Inc. (TSX: IMV; OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, has engaged Echelon Wealth Partners Inc. and National Bank Financial Inc. for a bought deal financing of 7,692,308 common shares at $1.30 per share for gross proceeds of approximately $10 million.

Proceeds will be used to advance the company’s various DepoVax™-based products clinical studies and for general corporate and working capital purposes.

News Release

Immunovaccine Announces $10 million Bought Deal Offering


Halifax, Nova Scotia; May 31, 2017 – Immunovaccine Inc. (“Immunovaccine” or the “Corporation”) (TSX:IMV) (OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, announced today that it has entered into a bought deal financing agreement to sell 7,692,308 common shares of the Corporation (the “Common Shares”) at a price of $1.30 per Common Share for gross proceeds of approximately $10 million (the “Offering”).

The Offering will be conducted through a syndicate of underwriters (the “Underwriters”) led by Echelon Wealth Partners Inc. and National Bank Financial Inc. and including Mackie Research Capital Corporation. Immunovaccine has granted the Underwriters an over-allotment option to purchase up to an additional 1,153,846 Common Shares at the offering price, exercisable for a period of 30 days after closing. If the over-allotment option is exercised in full, the gross proceeds from the Offering will be approximately $11.5 million.

The Corporation intends to use the net proceeds of the Offering to advance the Company’s various DepoVax™-based products clinical studies and for general corporate and working capital purposes.

The Common Shares will be offered by way of a short form prospectus to be filed in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Québec, Nova Scotia and Newfoundland and Labrador.

The Offering is expected to close on or about June 21, 2017 and is subject to customary closing conditions including, but not limited to, Toronto Stock Exchange’s approval.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Immunovaccine

Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies and infectious disease vaccines based on DepoVax™, the Corporation’s patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation and a phase 2 study with Merck assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The Corporation is also exploring additional applications of DepoVax™, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at

Contacts for Immunovaccine:

Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E:

Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E:
Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E:

SOURCE: Immunovaccine Inc.